Regenxbio, UPenn file second patent suit against Sarepta over DMD therapy

Regenxbio (NASDAQ:RGNX) said that it and the University of Pennsylvania have filed a second patent infringement suit against Sarepta Therapeutics (NASDAQ:SRPT) over Sarepta's therapy candidate SRP-9001 for the treatment of Duchenne muscular dystrophy.

The suit alleges that Sarepta has infringed upon a patent held by UPenn and exclusively licensed to Regenxbio. The plaintiffs are seeking compensation for the alleged infringement, Regenxbio said.

Regenxbio said that this is the second patent infringement lawsuit it and UPenn have filed against Sarepta. The plaintiffs filed a suit in September 2020 alleging that Sarepta had infringed upon a UPenn patent covering certain culture host cell technology in its manufacturing of SRP-9001. A trial for that case is slated for January 2024.

Sarepta's SRP-9001 marketing application is currently being reviewed by the US Food and Drug Administration. Last month, the company said it expected the review to be completed by June 22.

Regenxbio is also developing a treatment for the disease called RGX-202. The company received fast track status for the product in April.

More on Regenxbio:

Regenxbio's gene therapy for Hunter syndrome gets FDA regenerative medicine status

Regenxbio stock pops on FDA fast track tag for Duchenne gene therapy RGX-202

FDA to back accelerated approval pathway for gene therapies